Grail Stock Faces Volatility After NHS Trial Results Miss Expectations
Grail's stock has declined significantly following a failed primary endpoint in its large-scale NHS England trial for Galleri, despite strong revenue growth and narrowing losses. The setback may delay FDA approval and broader adoption of the cancer detection test.
Topics: biotech clinical_trials FDA investing